PE20011270A1 - [5-CYCLOPROPIL-1- (2-QUINOLON-5-IL) -1H-PIRAZOL-4-CARBONYL] GUANIDINE AS AN INHIBITOR OF THE SODIUM-HYDROGEN EXCHANGER TYPE 1 (NHE-1) - Google Patents

[5-CYCLOPROPIL-1- (2-QUINOLON-5-IL) -1H-PIRAZOL-4-CARBONYL] GUANIDINE AS AN INHIBITOR OF THE SODIUM-HYDROGEN EXCHANGER TYPE 1 (NHE-1)

Info

Publication number
PE20011270A1
PE20011270A1 PE2001000376A PE2001000376A PE20011270A1 PE 20011270 A1 PE20011270 A1 PE 20011270A1 PE 2001000376 A PE2001000376 A PE 2001000376A PE 2001000376 A PE2001000376 A PE 2001000376A PE 20011270 A1 PE20011270 A1 PE 20011270A1
Authority
PE
Peru
Prior art keywords
quinolon
guanidine
carbonyl
cyclopropil
pirazol
Prior art date
Application number
PE2001000376A
Other languages
Spanish (es)
Inventor
Angel Guzman-Perez
Eric David Cox
Weichao George Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20011270A1 publication Critical patent/PE20011270A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I [5-CICLOPROPIL-1-(2-QUINOLON-5-IL)-1H-PIRAZOL-4-CARBONIL]GUANIDINA CON LA CONDICION DE QUE EL COMPUESTO [5-CICLOPROPIL-1-(QUINOLON-5-IL)-1H-PIRAZOL-4-CARBONIL]GUANIDINA NO SE INCLUYA. LA DOSIS ES DE 0,01mg/kg/DIA A 50 mg/kg/DIA Y SE ADMINISTRA DE MODO PROFILACTICO, ANTES O DURANTE LA CIRUGIA Y EN LAS 24 HORAS SIGUIENTES A LA CIRUGIA. SE REFIERE TAMBIEN A UN COMPOSICION FARMACEUTICA. EL COMPUESTO DE FORMULA I ES UN INHIBIDOR DEL INTERCAMBIADOR DE SODIO-HIDROGENO TIPO 1 (NHE-1) Y ES UTIL PARA ES UTIL PARA REDUCIR LAS LESIONES TISULARES RESULTANTE DE LA ISQUEMIA O HIPOXIA EN DIFERENTES TEJIDOSREFERS TO A COMPOUND OF FORMULA I [5-CYCLOPROPIL-1- (2-QUINOLON-5-IL) -1H-PIRAZOL-4-CARBONYL] GUANIDINE WITH THE CONDITION THAT THE [5-CYCLOPROPYL-1- (QUINOLON -5-IL) -1H-PYRAZOLE-4-CARBONYL] GUANIDINE NOT INCLUDED. THE DOSE IS FROM 0.01mg / kg / DAY TO 50mg / kg / DAY AND IS ADMINISTERED PROPHYLACTICLY, BEFORE OR DURING SURGERY AND IN THE 24 HOURS AFTER SURGERY. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THE COMPOUND OF FORMULA I IS AN INHIBITOR OF THE SODIUM-HYDROGEN EXCHANGER TYPE 1 (NHE-1) AND IS USEFUL TO REDUCE TISSUE INJURIES RESULTING FROM ISCHEMIA OR HYPOXIA IN DIFFERENT TISSUES

PE2001000376A 2000-04-28 2001-04-26 [5-CYCLOPROPIL-1- (2-QUINOLON-5-IL) -1H-PIRAZOL-4-CARBONYL] GUANIDINE AS AN INHIBITOR OF THE SODIUM-HYDROGEN EXCHANGER TYPE 1 (NHE-1) PE20011270A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20043200P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
PE20011270A1 true PE20011270A1 (en) 2001-12-12

Family

ID=22741697

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000376A PE20011270A1 (en) 2000-04-28 2001-04-26 [5-CYCLOPROPIL-1- (2-QUINOLON-5-IL) -1H-PIRAZOL-4-CARBONYL] GUANIDINE AS AN INHIBITOR OF THE SODIUM-HYDROGEN EXCHANGER TYPE 1 (NHE-1)

Country Status (40)

Country Link
EP (1) EP1276737A1 (en)
JP (1) JP2003531900A (en)
KR (1) KR20020093079A (en)
CN (1) CN1225466C (en)
AP (1) AP2002002651A0 (en)
AR (1) AR028375A1 (en)
AU (1) AU2001235896A1 (en)
BG (1) BG107139A (en)
BR (1) BR0110268A (en)
CA (1) CA2407535A1 (en)
CO (1) CO5221125A1 (en)
CR (1) CR6797A (en)
CZ (1) CZ20023408A3 (en)
DZ (1) DZ3310A1 (en)
EA (1) EA004882B1 (en)
EE (1) EE200200615A (en)
GT (1) GT200100064A (en)
HN (1) HN2001000042A (en)
HR (1) HRP20020851A2 (en)
HU (1) HUP0300651A2 (en)
IL (1) IL152075A0 (en)
IS (2) IS6567A (en)
MA (1) MA26897A1 (en)
MX (1) MXPA02010600A (en)
MY (1) MY133842A (en)
NO (1) NO20025132L (en)
NZ (1) NZ521348A (en)
OA (1) OA12256A (en)
PA (1) PA8513301A1 (en)
PE (1) PE20011270A1 (en)
PL (1) PL357765A1 (en)
SK (1) SK14872002A3 (en)
SV (1) SV2002000418A (en)
TN (1) TNSN01065A1 (en)
TR (1) TR200202439T2 (en)
UA (1) UA73348C2 (en)
UY (1) UY26680A1 (en)
WO (1) WO2001083470A1 (en)
YU (1) YU79602A (en)
ZA (1) ZA200208605B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006872A (en) * 2001-01-31 2003-11-13 Pfizer Prod Inc Ethanolates of sodium-hydrogen exchanger type-1 inhibitor.
CA2469305A1 (en) * 2001-12-19 2003-06-26 Frank Robert Busch Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
EP1499317A1 (en) * 2002-05-02 2005-01-26 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors
FR2840302B1 (en) * 2002-06-03 2004-07-16 Aventis Pharma Sa ISOINDOLONE DERIVATIVES, PREPARATION METHOD AND INTERMEDIARY THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
ES2220185B1 (en) * 2002-07-16 2006-04-01 Consejo Sup. De Investig. Cientificas NEW INHIBITOR PEPTIDE OF THE NA + / H + EXCHANGER (PINHE), AND ITS APPLICATIONS.
US7550480B2 (en) * 2003-02-14 2009-06-23 Smithkline Beecham Corporation Compounds
RU2518741C1 (en) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" MEDICATION, INHIBITING Na+/H+-EXCHANGE, AND HALOGENIDES OF 1-DIALKYLAMINOETHYL-3-[SUBSTITUTED(DISUBSTITUTED)PHENACYL]-2-AMINOBENZIMIDAZOLIUM

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1056729B1 (en) * 1998-02-27 2004-12-29 Pfizer Products Inc. N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl]guanidine derivatives for the treatment of ischemia

Also Published As

Publication number Publication date
EA200201023A1 (en) 2003-02-27
MA26897A1 (en) 2004-12-20
YU79602A (en) 2006-05-25
ZA200208605B (en) 2003-10-24
OA12256A (en) 2003-11-06
AU2001235896A1 (en) 2001-11-12
UA73348C2 (en) 2005-07-15
GT200100064A (en) 2002-03-22
IL152075A0 (en) 2003-05-29
HRP20020851A2 (en) 2005-02-28
CR6797A (en) 2004-05-17
EP1276737A1 (en) 2003-01-22
TR200202439T2 (en) 2003-02-21
SK14872002A3 (en) 2004-03-02
UY26680A1 (en) 2001-12-28
CN1225466C (en) 2005-11-02
PA8513301A1 (en) 2003-09-05
NZ521348A (en) 2004-09-24
EE200200615A (en) 2004-04-15
HN2001000042A (en) 2001-07-09
BG107139A (en) 2003-07-31
DZ3310A1 (en) 2001-11-07
WO2001083470A1 (en) 2001-11-08
CZ20023408A3 (en) 2004-01-14
CA2407535A1 (en) 2001-11-08
CO5221125A1 (en) 2002-11-28
EA004882B1 (en) 2004-08-26
NO20025132L (en) 2002-12-12
AP2002002651A0 (en) 2002-12-31
AR028375A1 (en) 2003-05-07
IS6588A (en) 2002-10-21
MY133842A (en) 2007-11-30
JP2003531900A (en) 2003-10-28
BR0110268A (en) 2003-12-30
MXPA02010600A (en) 2003-03-10
HUP0300651A2 (en) 2003-07-28
KR20020093079A (en) 2002-12-12
IS6567A (en) 2002-09-24
SV2002000418A (en) 2002-07-03
TNSN01065A1 (en) 2005-11-10
CN1426404A (en) 2003-06-25
PL357765A1 (en) 2004-07-26
NO20025132D0 (en) 2002-10-25

Similar Documents

Publication Publication Date Title
MXPA03005464A (en) Antiviral agents.
DK1697370T3 (en) Azabicyclic heterocyclic compounds as cannabinoid receptor modulators
UY26977A1 (en) IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS
PA8593001A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
SE0202463D0 (en) Novel compounds
GT200100137A (en) PRO-DRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES.
BRPI0313942B8 (en) benzimidazole derivatives useful as antiproliferative agents, their preparation processes, pharmaceutical composition comprising the same and uses of said compounds in the preparation of pharmaceutical compositions
PA8591701A1 (en) PIRROLOPIRIMIDINE DERIVATIVES
ECSP024393A (en) SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH
ECSP077185A (en) PIRIDINE DERIVATIVES
MY123310A (en) Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions
UY27872A1 (en) CASPASA INHIBITORS AND USES OF THE SAME.
SE0302573D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
PE20011270A1 (en) [5-CYCLOPROPIL-1- (2-QUINOLON-5-IL) -1H-PIRAZOL-4-CARBONYL] GUANIDINE AS AN INHIBITOR OF THE SODIUM-HYDROGEN EXCHANGER TYPE 1 (NHE-1)
AR064543A1 (en) USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS
TR200102008T2 (en) Use of pyridine derivatives for prophylaxis and treatment of cerebral ischemia.
BR0311363A (en) Immediate release pharmaceutical formulation, use thereof, and method for treating a cardiovascular disorder in a patient
UA83832C2 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
MXPA05006889A (en) Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
BRPI9509819B8 (en) enterokinetic benzamide and pharmaceutical composition comprising the same
SE0302572D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CO5210898A1 (en) SYNERGIC COMBINATIONS OF FUNGICIDE OF VALINAMIDA AND FENAMIDONA TYPE
ECSP055673A (en) DERIVATIVES OF 4- (3,5-DICIANOPHENOXI) PIRAZOL FOR USE AS REVERSE TRANSCRIPTASE MODULATORS IN HIV TREATMENT
PA8450901A1 (en) Erythromycin derivatives

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed